Search research articles
Contact Us
Filters
Showing results (21-30 of 326) with videos related to
Page
of 33
Sort By:
The American Journal of Cardiology
|
January 25, 1985
Therapeutic application of calcium-channel antagonists for pulmonary hypertension
M Packer
Journal of Cardiovascular Pharmacology
|
January 1, 1989
Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with beta-adrenergic agonists and antagonists
M Packer
The New England Journal of Medicine
|
June 4, 1987
Do vasodilators prolong life in heart failure?
M Packer
Journal of the American College of Cardiology
|
November 1, 1989
Second generation calcium channel blockers in the treatment of chronic heart failure: are they any better than their predecessors?
M Packer
The American Journal of Cardiology
|
March 6, 1990
Hormone-electrolyte interactions in congestive heart failure: lessons from a 4,000-year-old Sumerian tablet
M Packer
Chest
|
October 1, 1985
Does pulmonary vasoconstriction play an important role in patients with primary pulmonary hypertension? A skeptic's view of vasodilator therapy
M Packer
Circulation
|
September 15, 1995
Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?
M Packer
Circulation
|
August 1, 1990
Pathophysiological mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure
M Packer
Lancet (London, England)
|
July 11, 1992
Treatment of chronic heart failure
M Packer
Journal of the American College of Cardiology
|
July 1, 1992
The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure
M Packer
Page
of 33
Search research articles
Search
Showing results (21-30 of 326) with videos related to
Sort By:
Page
of 33
The American Journal of Cardiology
|
January 25, 1985
Therapeutic application of calcium-channel antagonists for pulmonary hypertension
M Packer
Journal of Cardiovascular Pharmacology
|
January 1, 1989
Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with beta-adrenergic agonists and antagonists
M Packer
The New England Journal of Medicine
|
June 4, 1987
Do vasodilators prolong life in heart failure?
M Packer
Journal of the American College of Cardiology
|
November 1, 1989
Second generation calcium channel blockers in the treatment of chronic heart failure: are they any better than their predecessors?
M Packer
The American Journal of Cardiology
|
March 6, 1990
Hormone-electrolyte interactions in congestive heart failure: lessons from a 4,000-year-old Sumerian tablet
M Packer
Chest
|
October 1, 1985
Does pulmonary vasoconstriction play an important role in patients with primary pulmonary hypertension? A skeptic's view of vasodilator therapy
M Packer
Circulation
|
September 15, 1995
Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?
M Packer
Circulation
|
August 1, 1990
Pathophysiological mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure
M Packer
Lancet (London, England)
|
July 11, 1992
Treatment of chronic heart failure
M Packer
Journal of the American College of Cardiology
|
July 1, 1992
The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure
M Packer
Page
of 33